Methods of treating neuromyelitis optica spectrum disorder
AssigneeViela Bio, Inc.
InventorsWilliam REES, Eliezer KATZ, Michael SMITH, Nanette MITTEREDER
Life of this patent
Estimating the term…
Abstract
Methods of treating neuromyelitis optica spectrum disorder (NMOSD) are disclosed herein. In particular, methods of treating NMOSD in a subject identified as having a higher or lower level of NMOSD-disease activity, e.g., by serum glial fibrillary acidic protein concentration, are provided.
Claims32
1-59. (canceled)
A method of treating neuromyelitis optica spectrum disorder (NMOSD) in a subject in need thereof, the method comprising administering a therapeutically effective amount of a B cell depleting therapy to the subject in need thereof, wherein a sample of the subject has an elevated glial fibrillary acidic protein (GFAP) concentration.
A method of treating neuromyelitis optica spectrum disorder (NMOSD) in a subject in need thereof, the method comprising administering a therapeutically effective amount of Inebilizumab to the subject in need thereof, wherein a serum sample of the subject has an elevated concentration of a biomarker selected from the group consisting of:
- glial fibrillary acidic protein (GFAP), neurofilament light chain (NfL), ubiquitin carboxyl-terminal hydrolase L1 (UCH-L1), and TAU.
A method of treating neuromyelitis optica spectrum disorder (NMOSD) in a subject in need thereof, the method comprising administering Inebilizumab to a subject in need, wherein a sample of the subject is determined to have an elevated concentration of a biomarker of neuronal injury.
Dependencies are inferred from the claim text.